SOPHiA GENETICS Launches New Residual Acute Myeloid (RAM) Application

June 24, 2024

https://www.prnewswire.com/news-releases/sophia-genetics-launches-new-residual-acute-myeloid-ram-application-302179525.html

Novel application supports measurable residual disease (MRD) testing to help monitor cancer and stay ahead of relapse

BOSTON and ROLLE, Switzerland, June 24, 2024 /PRNewswire/ — SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced its new Residual Acute Myeloid (RAM) Application. The new offering expands the company’s comprehensive oncology portfolio to support measurable residual disease (MRD) capabilities and will be available to customers worldwide this summer.

Read more at prnewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.